Effects of placental protein 13 on the cardiovascular system in gravid and non-gravid rodents

Fetal Diagnosis and Therapy

Volumn 33, Issue 4, 2013, Pages 257-264

  Gizurarson, Sveinbjorn ^a   Huppertz, Berthold ^b   Osol, George ^c   Skarphedinsson, Jon Olafur ^a   Mandala, Maurizio ^c,d   Meiri, Hamutal ^e  

^a UNIVERSITY OF ICELAND   (Iceland)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c UNIVERSITY OF VERMONT   (United States)

^d UNIVERSITY OF CALABRIA   (Italy)

^e TeleMarpeh Ltd   (Israel)

Author keywords

Early pregnancy; First trimester; Galectins; Placental protein 13; Preeclampsia; Vasodilatation

Indexed keywords

PLACENTA PROTEIN; PLACENTA PROTEIN 13; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DIAMETER; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; DISEASE COURSE; ELEVATED BLOOD PRESSURE; FEMALE; HEART OUTPUT; HEART RATE; HEART STROKE VOLUME; HUMAN; IMMUNOBLOTTING; IN VIVO STUDY; ISOLATED ARTERY; LONG TERM EXPOSURE; MEAN ARTERIAL PRESSURE; MESENTERIC ARTERY; NONHUMAN; OSMOTIC PUMP; PLACENTA CIRCULATION; PREECLAMPSIA; PRIORITY JOURNAL; RAT; THERAPY EFFECT; UTERINE ARTERY; VASCULARIZATION; VASODILATATION; VEIN DIAMETER; VOLUME OF DISTRIBUTION;

EID: 84878449050     PISSN: 10153837     EISSN: 14219964     Source Type: Journal    
DOI: 10.1159/000345964     Document Type: Article

References (34)

1. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, 2002. American College of Obstetricians and Gynecologists. ACOG Committee on Obstetric Practice. Int J Gynaecol Obstet 2002; 77: 67-75
2. World Health Organization: Make Every Mother and Child Count. World Health Report, 2005. Geneva, World Health Organization, 2005
3. Huppertz B: Placental origins of preeclampsia: challenging the current hypothesis. Hypertension 2008; 51: 970-975
4. Cetin I, Huppertz B, Burton G, Cuckle H, Gonen R, Lapaire O, Mandia L, Nicolaides K, Redman C, Soothill P, Spencer K, Thilaganathan B, Williams D, Meiri H: Pregenesys preeclampsia markers consensus meeting: what do we require from markers, risk assessment and model systems to tailor preventive strategies? Placenta 2011; 32(suppl 1):S4-S16
5. Goswami D, Tannetta DS, Magee LA, Fuchisawa A, Redman CW, Sargent IL, von Dadelszen P: Excess syncytiotrophoblast microparticle shedding is a feature of early-onset preeclampsia, but not normotensive intrauterine growth restriction. Placenta 2006; 27: 56-61
6. Gupta AK, Rusterholz C, Huppertz B, Malek A, Schneider H, Holzgreve W, Hahn S: A comparative study of the effect of three different syncytiotrophoblast microparticles preparations on endothelial cells. Placenta 2005; 26: 59-66
7. Redman CW, Sargent IL: Latest advances in understanding preeclampsia. Science 2005; 308: 1592-1594
8. Redman CW, Sargent IL: Circulating microparticles in normal pregnancy and pre-eclampsia. Placenta 2008; 29(suppl A):S73-S77
9. Pijnenborg R, Vercruysse L, Hanssens M: Fetal-maternal conflict, trophoblast invasion, preeclampsia, and the red queen. Hypertension 2008; 27: 183-196
10. McNamara JM, Kay HH: Placental hormones: Physiology, disease, and prenatal diagnosis; in Kay HH, Nelson DM, Wang Y (eds): The Placenta. From Development to Disease. Oxford, Wiley-Blackwell, 2011, chapter 8, p 57
11. Burger O, Pick E, Zwickel J, Klayman M, Meiri H, Slotky R, Mandel S, Rabinovitch L, Paltieli Y, Admon A, Gonen R: Placental protein 13 (PP-13): effects on cultured trophoblasts, and its detection in human body fluids in normal and pathological pregnancies. Placenta 2004; 25: 608-622
12. Than NG, Pick E, Bellyei S, Szigeti A, Burger O, Berente Z, Janaky T, Boronkai A, Kliman H, Meiri H, Bohn H, Than GN, Sumegi B: Functional analyses of placental protein 13/ galectin-13. Eur J Biochem 2004; 271: 1065-1078
13. Balogh A, Pozsgay J, Matko J, Dong Z, Kim CJ, Varkonyi T, Sammar M, Rigo J, Meiri H, Romero R, Papp Z, Than NG: Placental protein 13(PP13/Galectin-13) undergoes lipid raft-associated subcellular redistribution in the syncytiotrophoblast in preterm preeclampsia and HELLP syndrome. Am J Obstet Gynecol 2011; 205: 156.e1-e14
14. Gonen R, Shahar R, Grimpel YI, Chefetz I, Sammar M, Meiri H, Gibor Y: Placental protein 13 as an early marker for pre-eclampsia: a prospective longitudinal study. BJOG 2008; 115: 1465-1472
15. Chafetz I, Kuhnreich I, Sammar M, Tal Y, Gibor Y, Meiri H, Cuckle H, Wolf M: First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol 2007; 197: 35. e1-e7
16. Romero R, Kusanovic JP, Than NG, Erez O, Gotsch F, Espinoza J, Edwin S, Chefetz I, Gomez R, Nien JK, Sammar M, et al: First-trimester maternal serum PP13 in the risk assessment for preeclampsia. Am J Obstet Gynecol 2008; 199: 122.e1-e11
17. Khalil A, Cowans NJ, Spencer K, Goichman S, Meiri H, Harrington K: First-trimester markers for the prediction of pre-eclampsia in women with a-priori high risk. Ultrasound Obstet Gynecol 2010; 35: 671-679
18. Worthelbrew EJ, Koster MP, Cuckle HS, Stoutenbeek PH, Schielen PC, Visser GH: First-trimester placental protein 13 and placental growth factor: markers for identification of women destined to develop early-onset pre-eclampsia. BJOG 2010; 117: 1384-1389
19. Huppertz B, Sammar M, Chefetz I, Neumaier-Wagner P, Bartz C, Meiri H: Longitudinal determination of serum placental protein 13 during development of preeclampsia. Fetal Diagn Ther 2008; 24: 230-236
20. Farina A, Zucchini C, Sekizawa A, Purwosunu Y, de Sanctis P, Santarsiero G, Rizzo N, Morano D, Okai T: Performance of messenger RNAs circulating in maternal blood in the prediction of preeclampsia at 10-14 weeks. Am J Obstet Gynecol 2010; 203:e1-e6
21. Sekizawa A, Purwosunu Y, Yoshimura S, Nakamura M, Shimizu H, Okai T, Rizzo N, Farina A: PP13 mRNA expression in trophoblasts from preeclamptic placentas. Reprod Sci 2009; 16: 408-413
22. Sammar M, Nisemblat S, Fleischfarb Z, Golan A, Sadan O, Meiri H, Huppertz B, Gonen R: Placenta-bound and body fluid PP13 and its mRNA in normal pregnancy compared to preeclampsia, HELLP and preterm delivery. Placenta 2011; 32(suppl):S30-S36
23. Than NG, Romero R, Goodman M, Weckle A, Xing J, Dong Z, Xu Y, Tarquini F, Szilagyi A, Gal P, Hou Z, Tarca AL, et al: A primate subfamily of galectins expressed at the maternal-fetal interface that promote immune cell death. Proc Natl Acad Sci USA 2009; 106: 9731-9736
24. Kliman HJ, Sammar M, Grimpel Y-I, Lynch SK, Milano KM, Pick E, Bejar J, Arad A, Lee JJ, Meiri H, Gonen R Placental protein 13 and decidual zones of necrosis: an immunologic diversion that may be linked to preeclampsia. Reproduct Sci, DOI: 10.1177/ 1933719111424445
25. Than NG, Romero R, Meiri H, Erez O, Xu Y, Targuini F, Barna L, Szilagvi A, Ackerman R, Sammar M, Fule T, et al: PP13, maternal ABO blood groups and the risk assessment of pregnancy complications. PLoS one 2011; 6:e21564
26. Svavarsdottir AH, Gizurarson S, Franzson L, Smarason AK: Functional behavior of placental protein 13 (PP13) and its involvement in preeclampsia, thesis; University of Iceland, 2008
27. Mohamood I: Application of allometric principles for the prediction of pharmacokinetics in human and veterinary drug development. Adv Drug Delivery Rev 2007; 59: 1177-1192
28. Mandala M, Gokina N, Barron C, Osol G: Endothelial-derived hyperpolarization factor (EDHF) contributes to PIGF-Induced dilation of mesenteric resistance arteries from pregnant rats. J Vasc Res 2012; 49: 43-49
29. Colton I, Mandala M, Morton J, Davidge ST, Osol G: Influence of constriction, wall tenstion, smooth muscle activation and cellular deformation on rat resistance artery vasodilator reactivity. Cell Physiol Biochem 2012; 29: 883-892
30. Visegrady B, Than NG, Kilar F, Sumegi B, Than GN, Bohn H: Homology modeling and molecular dynamics studies of human placental tissue protein 13 (galectin-13). Protein Eng 2001; 14: 875-880
31. Bjorklund N, Dantzer V, Leiser R: Comparative placentation in laboratory animals. Scand J Lab Anim Sci 1989; 16: 129-158
32. Than NG, Abdul Rahman O, Magenheim R, Nagy B, Fule T, Hargitai B, Sammar M, Hupuczi P, Tarca AL, Szabo G, Kovalszky I, Meiri H, Sziller I, Rigo J Jr, Romero R, Papp Z: Placental protein 13 (galectin-13) has decreased placental expression but increased shedding and maternal serum concentrations in patients presenting with preterm pre-eclampsia and HELLP syndrome. Virchows Arch 2008; 453: 387-400
33. Gebhardt S, Bruiners N, Hillerman R: A novel exonic variant (221delT) in the LGALS13 gene encoding placental protein 13 (PP13) is associated with preterm labour in a low risk population. J Reprod Immunol 2009: 82: 166-173
34. Soreq H, Wolf Y: NeurimmiRs: microRNAs in the neuroimmune interface. Trends Mol Med 2011; 17: 548-555.